Evaluation and Management of Sleep-Disordered Breathing in Dialysis Patients

Initial Assessment and Risk Stratification

The American College of Cardiology recommends that sleep-disordered breathing, which affects 34-37% of dialysis patients, requires immediate evaluation given the associated twofold increase in stroke risk and significantly elevated cardiovascular mortality 1
The National Kidney Foundation suggests assessing for signs of fluid overload during the dialysis session, including peripheral edema, abnormal lung sounds, and elevated jugular venous pressure, as pulmonary edema commonly causes respiratory disturbances in ESRD patients 2

The American Journal of Kidney Diseases recommends implementing strict sodium restriction (100 mmol/day) and appropriate ultrafiltration to achieve dry weight, as fluid overload directly contributes to sleep apnea 3
The American Academy of Sleep Medicine suggests initiating gabapentin 100-300 mg after each dialysis session as the preferred medication for sleep disorders in dialysis patients, given its proven efficacy and favorable safety profile in ESRD 4
The National Kidney Foundation advises prescribing strict sleep hygiene measures, including a consistent 7-8 hour sleep schedule, dark quiet environment, and leg elevation 2-3 hours before bed to reduce fluid redistribution that worsens sleep apnea 1

The American Psychological Association recommends screening for and treating depression, which has a prevalence of 22.8% in dialysis patients, as it is both a cause and consequence of sleep disturbance 1, 4
The European Renal Association suggests assessing and treating uremic pruritus, which affects 40% of dialysis patients, as it significantly disrupts sleep 4

The American Society of Nephrology recommends evaluating sleep quality and medication efficacy at each dialysis visit 4
The National Kidney Foundation advises reassessing fluid status regularly, as poor fluid control independently associates with decreased quality of life and contributes to sleep disturbances 1